Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This review synthesizes evidence linking aspirin use to reduced risk of calcific aortic valve disease in persons with elevated lipoprotein(a), highlighting the potential for targeted preventive strategies.
TAPIS subgroup analysis reveals that ticagrelor-aspirin combined with thrombolysis may improve outcomes in moderate ischemic stroke patients with multiple acute infarcts, without increasing hemorrhage risk, suggesting infarct pattern as a p
The STRATEGY trial assessed whether combining tirofiban with aspirin improves outcomes in branch atheromatous disease (BAD)-related stroke but found no significant benefit over aspirin alone in preventing neurological deterioration or recur
Universal dispensation of aspirin at 162 mg daily in high-risk pregnant populations reduces preeclampsia with severe features without increasing adverse maternal or neonatal outcomes, supporting broad aspirin use beyond risk-based prescribi
A 10-year follow-up of the ASPREE trial reveals that low-dose aspirin does not reduce cancer incidence in adults aged 70 and older, but is associated with increased cancer-related mortality, challenging long-held assumptions about aspirin&#
This review synthesizes current evidence on the efficacy and safety of ticagrelor combined with aspirin compared to aspirin alone following CABG for acute coronary syndrome, highlighting the 2025 TACSI trial and its implications for clinica
ASPREE randomized ~19,000 older adults to low‑dose aspirin or placebo. Over ~4.7 years, aspirin did not improve disability‑free survival or reduce cardiovascular events, increased major bleeding, and showed a surprising rise in cancer‑relat
Comprehensive review of ARIES-HM3 trial findings showing aspirin avoidance with vitamin K antagonists in HeartMate 3 LVAD patients reduces bleeding without increasing thrombotic events, supported by analyses across subgroups and anticoagula
A randomized trial revealed that adding aspirin to oral anticoagulation in chronic coronary syndrome patients increases adverse cardiovascular events, mortality, and major bleeding, challenging conventional dual therapy approaches.
A secondary analysis of the ARCADIA trial reveals that apixaban significantly reduces recurrent ischemic stroke risk compared to aspirin in patients with left ventricular systolic dysfunction post-cryptogenic stroke.
THEIA trial evaluated intravenous alteplase against oral aspirin in acute CRAO within 4.5 hours; no significant visual improvement difference was found, emphasizing the need for further research and meta-analyses to clarify thrombolysis ben
This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for thos
This meta-analysis of nearly 29,000 CAD patients shows clopidogrel monotherapy reduces major cardiovascular events more than aspirin without increasing major bleeding risk, supporting clopidogrel as preferred secondary prevention.
Extended follow-up from the ASPREE-XT study shows low-dose aspirin does not improve healthy lifespan—defined as survival free of dementia, persistent disability, or death—in healthy older adults, and its risks include increased major hemorr
The STOPDAPT-3 trial compared aspirin and clopidogrel monotherapy after short dual antiplatelet therapy in PCI patients, showing similar cardiovascular and bleeding outcomes at 1 year.
STOPDAPT-3 trial shows aspirin and clopidogrel yield comparable cardiovascular and bleeding outcomes 1 month to 1 year post-PCI in ACS patients, regardless of bleeding risk or STEMI status.
Early low-dose aspirin reduces early preterm birth risk and delays timing of delivery in women at high risk for preterm pre-eclampsia, with significant benefits in iatrogenic preterm births and small-for-gestational-age pregnancies.
The SAKK 41/13 trial provides the first prospective randomized evidence that adjuvant aspirin may improve disease-free survival in patients with resected PIK3CA-mutated stage II and III colon cancer, suggesting its potential as a safe, cost
This randomized trial confirms that daily low-dose aspirin significantly reduces colorectal cancer recurrence in patients with PI3K pathway mutations, highlighting a targeted adjunctive therapy option.
A large meta-analysis in The Lancet demonstrates that clopidogrel reduces MACCE risk by 14% over aspirin in CAD secondary prevention, with comparable safety over 5.5 years.